In this industry analysis, Scott Mazza, co-founder and COO of Vitality CBD, explains the scientific, legal, and practical distinctions between THC and its acidic precursor, THCA, focusing on how heat-driven conversion determines psychoactivity and regulatory status. Mazza reviews early research pointing to THCA’s potential anti-inflammatory, anti-nausea, and neuroprotective properties, while clearly noting that most evidence remains preclinical. He also assesses the unstable U.S. regulatory environment, highlighting proposed federal and state-level changes that could reshape the legality of THCA and emphasizing the need for clear standards, testing, and consumer diligence.

In this Wellbeing Magazine article, Scott Mazza, Co-Founder of Vitality CBD and Certified Headies, explains what THCA is, how it differs from THC, and why it has emerged as a legally distinct hemp-derived cannabinoid under the 2018 Farm Bill. Mazza outlines early scientific research suggesting potential anti-inflammatory, neuroprotective, and anti-nausea properties, while emphasizing that findings remain preliminary. He also examines the evolving regulatory landscape, warning that proposed changes to federal hemp law could significantly impact THCA’s legality and arguing for clear, science-based regulation rather than blanket product bans.

In this science-forward overview, Scott Mazza, co-founder and COO of Vitality CBD, examines the emerging research landscape around minor cannabinoids such as CBN, CBG, THCA, and THCV. The article synthesizes early findings on their distinct pharmacological profiles and potential applications, from sleep, pain, and inflammation to neuroprotection and skin health, while situating these compounds within the broader concept of the entourage effect. Mazza also addresses regulatory and quality challenges, arguing that evidence-based policy and rigorous research are essential to responsibly unlocking the therapeutic and nutritional potential of hemp’s lesser-known cannabinoids.

In this evidence-based guide, Scott Mazza, co-founder and COO of Vitality CBD, outlines emerging research and best practices for the responsible use of CBD in pets. The article reviews veterinary studies indicating that hemp-derived cannabinoids are generally well tolerated in dogs and cats at appropriate doses, with potential applications for conditions such as arthritis, anxiety, pain, and epilepsy. Mazza emphasizes careful dosing, species-specific formulations, veterinarian guidance, and rigorous product standards, including full-spectrum extracts and third-party testing, to ensure safety and efficacy for companion animals.

In this wellness-focused feature, Scott Mazza, co-founder and COO of Vitality CBD, reviews emerging research on CBD’s effects on exercise performance, anxiety, and perceived exertion. Drawing on peer-reviewed studies, the article explains how CBD may reduce exercise-related anxiety and improve subjective workout experiences without impairing performance, while also examining its potential role in recovery, inflammation, and sleep. Mazza emphasizes cautious adoption, product quality, and third-party testing as athletes and professional sports organizations increasingly evaluate cannabis compounds within training and wellness routines.

In this industry analysis, Scott Mazza, co-founder and COO of Vitality CBD, examines the scientific, legal, and regulatory uncertainties surrounding delta-8 THC as policymakers revisit the Farm Bill. The article explains how delta-8 is synthesized from hemp-derived CBD, outlines early findings on its milder psychoactive profile, and contrasts anecdotal consumer use with the current lack of rigorous clinical research. Mazza argues for science-based regulation focused on production standards and consumer safety, warning that outright prohibition could harm the hemp industry while failing to address the risks posed by poor manufacturing practices.

In this guest column, Scott Mazza, co-founder and COO of Vitality CBD, examines how advances in cannabis-based pain research are accelerating mainstream acceptance of cannabis and its compounds. Citing peer-reviewed studies on terpenes matching or exceeding morphine’s effects in neuropathic pain models, along with growing evidence around CBD’s role in pain modulation and opioid-related harm reduction, the article frames pain management as a central driver of cultural, medical, and legislative change. Mazza connects emerging science, professional sports adoption, and shifting public opinion to argue that effective, non-addictive pain treatments may be the key catalyst for broader cannabis normalization.

In this comparative analysis, Scott Mazza, co-founder and COO of Vitality CBD, examines the physiological and therapeutic differences between CBD and THC across anxiety, sleep, pain, and arthritis applications. Drawing on clinical trials and observational studies, the article explains how THC’s sedative and analgesic effects contrast with CBD’s non-psychoactive role in anxiety reduction, inflammation control, and sleep regulation, while noting evidence for combined formulations in certain pain contexts. Mazza emphasizes informed, condition-specific selection, cautious dosing, and the potential role of full-spectrum products, underscoring the need for continued research and responsible use.

In this science-focused article, Scott Mazza, co-founder and COO of Vitality CBD, reviews emerging research on CBD’s potential role in supporting women during menopause. Drawing on clinical and observational studies, the piece examines how CBD may help address common symptoms such as sleep disruption, joint pain, anxiety, and mood changes, while emphasizing evidence around full-spectrum formulations and dosing. Mazza also highlights the importance of product quality, third-party testing, and cautious application as scientific understanding and regulatory oversight continue to evolve.

In this April 2024 feature for The Bluntness, Scott Mazza, co-founder and COO of Vitality CBD, explains the role cannabinoids play within the entourage effect, alongside terpenes and flavonoids. The article outlines how different cannabinoids, ranging from THC and CBD to lesser-known compounds like CBG and CBN, interact with the endocannabinoid system and with each other to shape therapeutic and experiential outcomes. Citing emerging research and a 2022 clinical trial, Mazza highlights why full-spectrum CBD products may deliver effects at lower doses, reinforcing the importance of compound synergy, product composition, and informed consumer experimentation.

In this April 2024 analysis, Scott Mazza, co-founder and COO of Vitality CBD, examines emerging research comparing CBD and THC for anxiety management. Drawing on a four-week study of 300 participants published in Cannabis and Cannabinoid Research, the article reports that CBD-dominant formulations produced the most consistent anxiety reduction with fewer cognitive side effects than THC-dominant products. Mazza underscores the importance of dosing, product quality, and third-party testing, positioning CBD as a well-tolerated, evidence-supported option while emphasizing the need for continued clinical research.

In this article, Scott Mazza reviews emerging scientific evidence that begins to establish evidence-based daily intake limits for CBD, addressing a long-standing gap in consumer safety guidance. Drawing on a 2023 toxicological review and recent clinical findings, the article outlines proposed upper limits for different adult populations, including stricter thresholds for pregnancy, lactation, and liver risk. Mazza frames these dosage benchmarks as a critical step toward clearer labeling, improved regulatory decision-making, and a more mature, science-led CBD industry.